Pathophysiology and management of risperidone-induced sialorrhea: case report.

adverse reactions antipsychotics iloperidone psychopharmacology schizophrenia second-generation antipsychotics

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2023
Historique:
received: 13 03 2023
accepted: 27 06 2023
medline: 31 7 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: epublish

Résumé

Among antipsychotics, sialorrhea is most associated with clozapine, and when it occurs, it is uncomfortable, socially stigmatizing, and can contribute to medication non-adherence. Risperidone has a generally negligible muscarinic activity compared to clozapine, and yet, multiple reports of severe sialorrhea associated with risperidone have been reported. This case report describes risperidone-induced sialorrhea that was unintentionally masked by simultaneous clonidine administration that was intended to treat hypertension. Interestingly, sialorrhea was present but mild when clonidine was present; however, when risperidone was further titrated and clonidine removed, a significant worsening of sialorrhea developed. Sialorrhea did not respond to treatment with anticholinergic medication. The pathophysiology of antipsychotic-induced sialorrhea is complex and varies between antipsychotics. Risperidone-induced sialorrhea is suspected of having prominent adrenergic pathophysiology that is likely composed of highly viscoelastic saliva (high protein content), differing from the more commonly encountered clozapine-induced sialorrhea. Risperidone-induced sialorrhea is reported as more likely to respond to dose reduction and treatment with α2-adrenergic receptor agonists or β-adrenergic receptor antagonists and less likely to respond to anticholinergic (antimuscarinic) medications.

Sections du résumé

Background UNASSIGNED
Among antipsychotics, sialorrhea is most associated with clozapine, and when it occurs, it is uncomfortable, socially stigmatizing, and can contribute to medication non-adherence. Risperidone has a generally negligible muscarinic activity compared to clozapine, and yet, multiple reports of severe sialorrhea associated with risperidone have been reported.
Case presentation UNASSIGNED
This case report describes risperidone-induced sialorrhea that was unintentionally masked by simultaneous clonidine administration that was intended to treat hypertension. Interestingly, sialorrhea was present but mild when clonidine was present; however, when risperidone was further titrated and clonidine removed, a significant worsening of sialorrhea developed. Sialorrhea did not respond to treatment with anticholinergic medication.
Conclusion UNASSIGNED
The pathophysiology of antipsychotic-induced sialorrhea is complex and varies between antipsychotics. Risperidone-induced sialorrhea is suspected of having prominent adrenergic pathophysiology that is likely composed of highly viscoelastic saliva (high protein content), differing from the more commonly encountered clozapine-induced sialorrhea. Risperidone-induced sialorrhea is reported as more likely to respond to dose reduction and treatment with α2-adrenergic receptor agonists or β-adrenergic receptor antagonists and less likely to respond to anticholinergic (antimuscarinic) medications.

Identifiants

pubmed: 37520231
doi: 10.3389/fpsyt.2023.1185750
pmc: PMC10372792
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1185750

Informations de copyright

Copyright © 2023 Torrico and Kahlon.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Curr Drug Targets. 2004 Aug;5(6):573-9
pubmed: 15270204
Schizophr Res. 2007 Jul;93(1-3):410-1
pubmed: 17462863
Laryngoscope. 2004 Oct;114(10):1801-4
pubmed: 15454775
Laryngoscope. 2002 Jan;112(1):73-81
pubmed: 11802042
J Clin Psychopharmacol. 2001 Dec;21(6):608-11
pubmed: 11763010
Br J Clin Pharmacol. 1989 Sep;28(3):366-8
pubmed: 2789932
J Clin Psychopharmacol. 1992 Feb;12(1):69-70
pubmed: 1552044
Psychopharmacology (Berl). 2006 Apr;185(3):265-73
pubmed: 16514524
J Clin Psychopharmacol. 1994 Aug;14(4):283
pubmed: 7962689
J Clin Endocrinol Metab. 2006 Dec;91(12):5130-3
pubmed: 16968802
J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):480-484
pubmed: 35943409
J Psychiatry Neurosci. 2001 May;26(3):253
pubmed: 11394196
Psychiatr Q. 1992 Spring;63(1):51-70
pubmed: 1438605
Pharmacotherapy. 2000 Sep;20(9):1092-5
pubmed: 10999502
J Neurol Sci. 1996 Aug;139 Suppl:43-4
pubmed: 8899657
J Child Adolesc Psychopharmacol. 2012 Jun;22(3):254-5
pubmed: 22537186
Pharmacopsychiatry. 2010 Nov;43(7):282-3
pubmed: 20927701
Periodontol 2000. 2016 Feb;70(1):11-25
pubmed: 26662479
Psychosomatics. 2001 May-Jun;42(3):276
pubmed: 11351120
Behav Pharmacol. 2008 Sep;19(5-6):543-7
pubmed: 18690108

Auteurs

Tyler Torrico (T)

Kern Medical, Department of Psychiatry, Bakersfield, CA, United States.
American Psychiatric Association Substance Abuse and Mental Health Services Administration (SAMHSA) Minority Fellowship, Washington, DC, United States.

Angad Kahlon (A)

Kern Medical, Department of Psychiatry, Bakersfield, CA, United States.

Classifications MeSH